Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AstraZeneca
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 02 Nov 2017 Planned End Date changed from 2 Jan 2019 to 1 Jan 2019.
- 02 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 31 Jan 2018.